Search results
Showing 1096 to 1110 of 2580 results for methods
Biographies and registered interests for members of the Technology Appraisal Committee A
NICE has developed a medtech innovation briefing (MIB) on the S-Cath System for suprapubic catheterisations
Linzagolix for treating moderate to severe symptoms of uterine fibroids (TA996)
Evidence-based recommendations on linzagolix (Yselty) for treating moderate to severe symptoms of fibroids in adults of reproductive age.
Evidence-based recommendations on insertion of customised exposed titanium implants, without soft tissue cover, for complex orofacial reconstruction. This involves making the titanium implants specially to fit the person using a model of their face.
View recommendations for HTG313Show all sections
Sections for HTG313
Radiofrequency cold ablation for respiratory papillomatosis (HTG295)
Evidence-based recommendations on radiofrequency cold ablation for respiratory papillomatosis. This involves using an electrical current to dissolve or shrink the papillomas (non-cancerous growths).
View recommendations for HTG295Show all sections
Sections for HTG295
Percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolism (HTG705)
Evidence-based recommendations on percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolism. This involves removing the clot through a catheter inserted into a vein.
View recommendations for HTG705Show all sections
NICE has developed a medtech innovation briefing (MIB) on RenalSense Clarity RMS for acute kidney injury .
Guselkumab for treating moderate to severe plaque psoriasis (TA521)
Evidence-based recommendations on guselkumab (Tremfya) for treating moderate to severe plaque psoriasis in adults.
Our projects and partnerships help us anticipate and adapt to policy developments, including changes in health and social care delivery.
Evidence-based recommendations on percutaneous laser coronary angioplasty. This involves using a laser to burn away the deposits blocking the blood vessels of the heart.
View recommendations for HTG250Show all sections
Sections for HTG250
Baricitinib for moderate to severe rheumatoid arthritis (TA466)
Evidence-based recommendations on baricitinib (Olumiant) for moderate to severe rheumatoid arthritis in adults.
Evidence-based recommendations on vismodegib (Erivedge) for treating basal cell carcinoma in adults.
This guide describes the process NICE uses to develop indicators from NICE quality standards, NICE guidance or other sources of high-quality evidence
This guideline covers diagnosing and treating fertility problems. It aims to reduce variation in practice and improve the way fertility problems are investigated and managed.
Evidence-based recommendations on pembrolizumab (Keytruda) for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency in adults.